Obese Non DiabeticNCT05028803
The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acids
A study testing sodium phenylbutyrate in people with Obese Non Diabetic, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
The aim of this study is to reduce fasting circulating BCAA concentrations in volunteers using Sodium Phenylbutyrate. In addition, we aim investigate the effect of BCAA lowering on fasting blood glucose levels, insulin sensitivity measures and muscle metabolism. Read more about this study
- Who is it for?
- Ages 18 to 60 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Obese Non Diabetic
- What is being tested?
- sodium phenylbutyrate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Sep 2021to 1 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- • Participant is willing and able to give informed consent for participation in the study
- Not currently taking any medications
- Males between the ages of 18 - 60
- BMI ≥ 30 kg·m2
- FBG ≥ 6 mmol/L ≤ 7mmol/L or HbA1c ≥ 42 mmol/mol 48 ≤ mmol/mol
Who cannot join
- • Specify any diseases/disorders/ conditions that would preclude entry into the study
- Females
- History or current psychiatric illness
- History or current neurological condition (e.g. epilepsy)
- Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (this must remain for ALL UoN FMHS UREC approved studies)
- A BMI < 30kg·m2
Show all 15Show fewer
- FBG >7mmol/L/ or HbA1c >48mmol/mol
- Metabolic disease; Active inflammatory bowel disease
- Chronic kidney disease
- Malignancy
- Recent (6 mo) steroid/ hormone therapy
- Clotting dysfunction
- Musculoskeletal/ neurological disorders
- Active cardiovascular disease or recent cardiac event
- Respiratory disease (not including well-controlled asthma)
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University of Nottingham
Derby, Derbyshire, DE22 3NE
About this study
Official title: The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acid Concentrations in Obese and Prediabetics.
The aim of this study is to reduce fasting circulating BCAA concentrations in volunteers using Sodium Phenylbutyrate. In addition, we aim investigate the effect of BCAA lowering on fasting blood glucose levels, insulin sensitivity measures and muscle metabolism.
Read the detailed description
A total of twenty proteinogenic amino acids are present in the human body1. Due to their chemical structure, three of the amino acids - isoleucine, leucine and valine, are termed branched chain amino acids (BCAAs). Humans consume BCAAs through protein containing foods such as meat, eggs and milk2,3. However, recent studies, have revealed links between elevated plasma levels of BCAAs and type 2 diabetes (T2D), insulin resistance (IR) and obesity4-6. Such is the strength of these links that elevated blood concentration of BCAAs are considered biomarkers and prognostic factors for obesity, insulin resistance and type 2 diabetes7-9. Collectively, these data suggest that targeting dysregulation of BCAAs by reducing BCAA levels could offer important therapeutic value. Various methods can be implemented in order to reduce circulating fasting BCAA concentrations one method that our department has successfully implemented includes the restriction of BCAAs in 6 healthy volunteer participants through diet control. By restricting BCAA in the diets of healthy individuals, we successfully reduced fasting circulating BCAAs by 50% in just seven days. However, the construction of the diet was very time consuming, tedious, and longer studies would be plagued with compliance issues. This has led us to try an alternative method, which is to lower BCAA levels using Sodium Phenylbutyrate (NaPB). NaPB is a commonly used medication to treat patients with urea cycle disorders (UCD). However, it seems a secondary effect of the drug is to reduce circulating BCAA levels in volunteers. Lindsey Burrage et al 2014, reported significantly lower circulating BCAAs in volunteers receiving NaPB when compared to subjects not receiving NaPB10. Although the mechanisms are not fully understood it has been suggested that NaPB causes depletion of glutamine in the blood which may activate BCAA catabolism and thus cause a reduction in circulating plasma BCAAs11. It is our aim to use NaPB to lower BCAAs in prediabetic and obese participants.
Screening Visit Volunteers will sign a consent form, A health assessment, including an ECG to monitor your heart, a blood pressure check, height and weight measurement and a medical history check A fasted blood sample to measure health parameters, including glucose, HbA1c, liver and kidney function, lipid profiles, thyroid function and full blood count.
Once we received the details and results (within 1 week) from your screening session, we will contact you regarding your suitability. If you are suitable, we (you and the research team together) will decide on the dates to start the programme.
Instruct you in the completion of a food diary. STUDY DAY 0 For this day, we will ask volunteers to attend after an overnight fast (except water). We will take small samples of your blood (fasting sample).
After the blood samples participants will receive a 'heavy water' drink called Deuterium Oxide (D2O). This is almost the same as normal water, but a small and harmless chemical change allows us to calculate how much new muscle your body is making. The amount of D2O you are given will be calculated based on your body weight. Participants will provide saliva samples before and after receiving D2O. Before they go home they will receive small daily top-ups of D2O and asked to collect your saliva 3 hours after taking your daily top-ups for the first week, and twice weekly thereafter and keep the saliva samples in a fridge/freezer.
STUDY DAY 7 On return for the second study day participants will also bring with them saliva samples from the last 7 days. For this day, again volunteers are to attend after an overnight fast (except water). We will perform a muscle biopsy (fasting sample) to use as our baseline/pre-intervention measures. A fully qualified medical practitioner will take muscle biopsies. Biopsies are sterile procedures, with local anaesthetic.
Muscle biopsies Muscle biopsies will be taken from the thigh. Before the biopsy, the area will be cleaned and anaesthetised with local anaesthetic, after which a small (approx. 1cm wide, 2-3cm deep) incision will be made through the skin. The muscle biopsy (smaller than the size of a pea) will then be removed from the thigh using conchotome forceps (essentially a sharp pair of tweezers), with 3-5 small pieces taken to ensure adequate sampling. The incision will then be stitched shut and covered with a waterproof adhesive dressing. Muscle biopsies are usually well tolerated, largely painless (though the insertion is felt) and the complication rate is very low.
Biopsy Aftercare At the end of the biopsy, you will receive advice and information about how to take care of the wound and given an information leaflet. Five to seven days after each muscle biopsy, the stitches will be removed and the wounds will be checked.
In addition to the above, volunteers will also have a series of minimally and non-invasive tests to assess different aspects of your health and metabolic status:
- We will measure how well the body is able to process sugar by performing the oral glucose tolerance test (OGTT). This is usually used to diagnose diabetes, or stratify the future risk of diabetes. For this test, you will be given 75g of a sugary drink. Small blood samples will be taken prior to the drink and every 15 minutes (for 2 hours) from a cannula (thin plastic line) sited in a vein in your hand, which will be placed in a warm box.
- A light lunch will be provided at midday. After lunch the first oral dose of phenyl butyrate will be given.
- Volunteers will receive the first dose of Phenylbutyrate after lunch. Volunteers will receive 5 grams of sodium Phenylbutyrate every day. 5 g/m2/day of Sodium Phenylbutyrate will be split into three and taken with each meal.
- Participants will receive Sodium Phenylbutyrate to last one week. STUDY DAY 10 For this day, we will ask you to attend after an overnight fast (except water). We will take small samples of your blood (fasting sample). In addition, blood pressure, weight and height will be recorded. Volunteers will also have an ECG. It is anticipated study day 11 will take up to 1 hour to complete.
STUDY DAY 17 For this day, we will ask you to attend after an overnight fast (except water). We will take small samples of your blood (fasting sample) and a saliva sample to use as our midpoint intervention measures. In addition, blood pressure, weight and height will be recorded. Volunteers will then be provided with another medication organiser box with enough Sodium Phenylbutyrate to last them until the end of the study. It is anticipated study day 17 will take up to 1 hour to complete. We will also request a test for Leukopenia.
STUDY DAY 28 This is the final day of the study, again volunteers are to attend after an overnight fast (except water). A fully qualified medical practitioner will take muscle biopsies. Biopsies are sterile procedures, with local anaesthetic. Following this, we will perform the oral glucose tolerance test (OGTT), volunteers will be given 75g of a sugary drink. Small blood samples will be taken prior to the drink and every 15 minutes (for 2 hours) from a cannula which will be placed in a warm box In addition, blood pressure, weight and height will also be recorded. In addition a Fructosamine test will also be requested pre and post study.
- Conditions
- Obese Non Diabetic
- Being tested
- sodium phenylbutyrate
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sodium phenylbutyrateDrug
same as arm/group
| Study group | Role | What they receive |
|---|---|---|
| Phenylbutyrate | Experimental | Volunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day. Receives: Drug: sodium phenylbutyrate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum branched chain amino acids (BCAA) levels
Both total and individual BCAAs before and after intervention
Measured: 3 weeks
Secondary outcomes (2)
Musle protein syntyhesis (MPS)
Estimation via weekly sampling of saliva following deuterium oxide (D2O) tracer solution administration relative to baseline.
Measured: 4 weeks
Metabolic status (Oral glucose tolerance testing (OGTT))
Undertaken to assess for insulin sensitivity and resistance.
Measured: 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2021
- Study start1 Sep 2021
- Primary completion1 Sep 2023
- Study completion1 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obese Non DiabeticStudies of the same condition, open and under way.
- More trials run by University of NottinghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Philip Atherton, University of Nottingham
- Investigators
- Philip Prof Athertone, DM, Principal investigator, University of Nottingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05028803
- Sponsor's protocol ID
- _COMAP
- Other IDs
- 135-1220
- Status last verified
- Mar 2025
- First submitted
- 25 Aug 2021
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant medical information obtained as a result of this study are considered confidential and disclosure to third parties is prohibited with the exceptions noted above. Such medical information may be given to the participant's medical team and all appropriate medical personnel responsible for the participant's welfare. If information is disclosed during the study that could pose a risk of harm to the participant or others, the researcher will discuss this with the Chief Investigator (CI) and where appropriate report accordingly. Data generated as a result of this trial will be available for inspection on request by the participating physicians, the University of Nottingham representatives, the local Research Ethics Committee (REC) and the regulatory authorities. Elements of the results from this study will be submitted for peer-review in at least one publication.
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acid Concentrations in Obese and Prediabetics.
- ClinicalTrials.gov ID
- NCT05028803
- Acronym / sponsor ID
- _COMAP
- Conditions
- Obese Non Diabetic
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 1 Sep 2023 (actual)
- Study completion
- 1 Mar 2024 (actual)
- First posted
- 31 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to reduce fasting circulating BCAA concentrations in volunteers using Sodium Phenylbutyrate. In addition, we aim investigate the effect of BCAA lowering on fasting blood glucose levels, insulin sensitivity measures and muscle metabolism.
Detailed description
A total of twenty proteinogenic amino acids are present in the human body1. Due to their chemical structure, three of the amino acids - isoleucine, leucine and valine, are termed branched chain amino acids (BCAAs). Humans consume BCAAs through protein containing foods such as meat, eggs and milk2,3. However, recent studies, have revealed links between elevated plasma levels of BCAAs and type 2 diabetes (T2D), insulin resistance (IR) and obesity4-6. Such is the strength of these links that elevated blood concentration of BCAAs are considered biomarkers and prognostic factors for obesity, insulin resistance and type 2 diabetes7-9. Collectively, these data suggest that targeting dysregulation of BCAAs by reducing BCAA levels could offer important therapeutic value. Various methods can be implemented in order to reduce circulating fasting BCAA concentrations one method that our department has successfully implemented includes the restriction of BCAAs in 6 healthy volunteer participants through diet control. By restricting BCAA in the diets of healthy individuals, we successfully reduced fasting circulating BCAAs by 50% in just seven days. However, the construction of the diet was very time consuming, tedious, and longer studies would be plagued with compliance issues. This has led us to try an alternative method, which is to lower BCAA levels using Sodium Phenylbutyrate (NaPB). NaPB is a commonly used medication to treat patients with urea cycle disorders (UCD). However, it seems a secondary effect of the drug is to reduce circulating BCAA levels in volunteers. Lindsey Burrage et al 2014, reported significantly lower circulating BCAAs in volunteers receiving NaPB when compared to subjects not receiving NaPB10. Although the mechanisms are not fully understood it has been suggested that NaPB causes depletion of glutamine in the blood which may activate BCAA catabolism and thus cause a reduction in circulating plasma BCAAs11. It is our aim to use NaPB to lower BCAAs in prediabetic and obese participants.
Screening Visit Volunteers will sign a consent form, A health assessment, including an ECG to monitor your heart, a blood pressure check, height and weight measurement and a medical history check A fasted blood sample to measure health parameters, including glucose, HbA1c, liver and kidney function, lipid profiles, thyroid function and full blood count.
Once we received the details and results (within 1 week) from your screening session, we will contact you regarding your suitability. If you are suitable, we (you and the research team together) will decide on the dates to start the programme.
Instruct you in the completion of a food diary. STUDY DAY 0 For this day, we will ask volunteers to attend after an overnight fast (except water). We will take small samples of your blood (fasting sample).
After the blood samples participants will receive a 'heavy water' drink called Deuterium Oxide (D2O). This is almost the same as normal water, but a small and harmless chemical change allows us to calculate how much new muscle your body is making. The amount of D2O you are given will be calculated based on your body weight. Participants will provide saliva samples before and after receiving D2O. Before they go home they will receive small daily top-ups of D2O and asked to collect your saliva 3 hours after taking your daily top-ups for the first week, and twice weekly thereafter and keep the saliva samples in a fridge/freezer.
STUDY DAY 7 On return for the second study day participants will also bring with them saliva samples from the last 7 days. For this day, again volunteers are to attend after an overnight fast (except water). We will perform a muscle biopsy (fasting sample) to use as our baseline/pre-intervention measures. A fully qualified medical practitioner will take muscle biopsies. Biopsies are sterile procedures, with local anaesthetic.
Muscle biopsies Muscle biopsies will be taken from the thigh. Before the biopsy, the area will be cleaned and anaesthetised with local anaesthetic, after which a small (approx. 1cm wide, 2-3cm deep) incision will be made through the skin. The muscle biopsy (smaller than the size of a pea) will then be removed from the thigh using conchotome forceps (essentially a sharp pair of tweezers), with 3-5 small pieces taken to ensure adequate sampling. The incision will then be stitched shut and covered with a waterproof adhesive dressing. Muscle biopsies are usually well tolerated, largely painless (though the insertion is felt) and the complication rate is very low.
Biopsy Aftercare At the end of the biopsy, you will receive advice and information about how to take care of the wound and given an information leaflet. Five to seven days after each muscle biopsy, the stitches will be removed and the wounds will be checked.
In addition to the above, volunteers will also have a series of minimally and non-invasive tests to assess different aspects of your health and metabolic status:
- We will measure how well the body is able to process sugar by performing the oral glucose tolerance test (OGTT). This is usually used to diagnose diabetes, or stratify the future risk of diabetes. For this test, you will be given 75g of a sugary drink. Small blood samples will be taken prior to the drink and every 15 minutes (for 2 hours) from a cannula (thin plastic line) sited in a vein in your hand, which will be placed in a warm box.
- A light lunch will be provided at midday. After lunch the first oral dose of phenyl butyrate will be given.
- Volunteers will receive the first dose of Phenylbutyrate after lunch. Volunteers will receive 5 grams of sodium Phenylbutyrate every day. 5 g/m2/day of Sodium Phenylbutyrate will be split into three and taken with each meal.
- Participants will receive Sodium Phenylbutyrate to last one week. STUDY DAY 10 For this day, we will ask you to attend after an overnight fast (except water). We will take small samples of your blood (fasting sample). In addition, blood pressure, weight and height will be recorded. Volunteers will also have an ECG. It is anticipated study day 11 will take up to 1 hour to complete.
STUDY DAY 17 For this day, we will ask you to attend after an overnight fast (except water). We will take small samples of your blood (fasting sample) and a saliva sample to use as our midpoint intervention measures. In addition, blood pressure, weight and height will be recorded. Volunteers will then be provided with another medication organiser box with enough Sodium Phenylbutyrate to last them until the end of the study. It is anticipated study day 17 will take up to 1 hour to complete. We will also request a test for Leukopenia.
STUDY DAY 28 This is the final day of the study, again volunteers are to attend after an overnight fast (except water). A fully qualified medical practitioner will take muscle biopsies. Biopsies are sterile procedures, with local anaesthetic. Following this, we will perform the oral glucose tolerance test (OGTT), volunteers will be given 75g of a sugary drink. Small blood samples will be taken prior to the drink and every 15 minutes (for 2 hours) from a cannula which will be placed in a warm box In addition, blood pressure, weight and height will also be recorded. In addition a Fructosamine test will also be requested pre and post study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Phenylbutyrate | Experimental | Drug: sodium phenylbutyrateVolunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- • Participant is willing and able to give informed consent for participation in the study
Key exclusion criteria (15 listed)
- • Specify any diseases/disorders/ conditions that would preclude entry into the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sodium phenylbutyratesame as arm/group | Drug | Phenylbutyrate |
Primary outcome
Serum branched chain amino acids (BCAA) levels
Time frame: 3 weeks
Both total and individual BCAAs before and after intervention
2 secondary outcomes
Musle protein syntyhesis (MPS)
Time frame: 4 weeks
Metabolic status (Oral glucose tolerance testing (OGTT))
Time frame: 3 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
- Individual participant dataSharing planned: No. Individual participant medical information obtained as a result of this study are considered confidential and disclosure to third parties is prohibited with the exceptions noted above. Such medical information may be given to the participant's medical team and all appropriate medical personnel responsible for the participant's welfare. If information is disclosed during the study that could pose a risk of harm to the participant or others, the researcher will discuss this with the Chief Investigator (CI) and where appropriate report accordingly. Data generated as a result of this trial will be available for inspection on request by the participating physicians, the University of Nottingham representatives, the local Research Ethics Committee (REC) and the regulatory authorities. Elements of the results from this study will be submitted for peer-review in at least one publication.
Related trials for Obese Non Diabetic
RecruitingObservational study
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Obesity, Sarcopenia
Not yet recruiting
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
Obesity; Chronic Kidney Disease; Albuminuria
Not yet recruitingObservational study
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
RecruitingPhase 1
Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Active, not recruitingPhase 2
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
Overweight , Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philip Prof Athertone, DM principal investigator
University of Nottingham
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing sodium phenylbutyrate in people with Obese Non Diabetic, run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum branched chain amino acids (BCAA) levels (time frame: 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.